Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02070887 : Inhibiting COMT in Parkinson's Disease
AgesMin: 60 Years Max: 75 Years
Inclusion Criteria:

- Age 60 - 75 years,

- Caucasian ethnicity,

- diagnosed PD by UK brain bank criteria,

- Hoehn & Yahr scale 2 - 3,

- fertile females have to use contraception

- Group 1: medication with Stalevo® (L-DOPA/DDI + Entacapone)

- Group 2: medication with Madopar® or Sinemet® (L-DOPA/DDI)

Exclusion Criteria:

- methotrexate therapy during the last 12 months,

- treatment with Tolcapone

- vitamin B6, B12 and/or folic acid supplementation during last 6 months,

- pregnancy,

- intention to become pregnant during the course of the study,

- breast feeding,

- other clinically relevant concomitant disease states by discretion of the

- known or suspected non-compliance, drug or alcohol abuse,

- inability to follow the procedures of the study, e.g. due to language problems,
psychological disorders, dementia or confusional state of the subject,

- participation in another study with investigational drug within the 30 days preceding
and during the present study,

- enrolment of the investigator, his/her family members, employees and other dependent
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557